Post Mastectomy Hypofractionated Radiotherapy in High Risk Breast Cancer

October 22, 2017 updated by: Ahmed Ahm

A Prospective Phase 3 Clinical Trial Of Postmastectomy Hypofractionated Radiotherapy in High Risk Breast Cancer

The purpose of this study is to compare the efficacy and toxicities of hypofractionated radiotherapy with conventional fractionated radiotherapy in high risk breast cancer patients treated with mastectomy. It's hypothesized that the efficacy and toxicities are similar between the two groups.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Eligible breast cancer patients with mastectomy and axillary dissection are divided into two groups: conventional fractionated (CF) radiotherapy of 50 Gray (GY) in 25 fractions within 5 weeks to ipsilateral chest wall and supraclavicular nodal region, and hypofractionated (HF) radiotherapy of 43.5 Gray (GY) in 15 fractions within 3 weeks to the same region. During and after radiotherapy , the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Assiut, Egypt, 088
        • Recruiting
        • Assiut faculty of medicine , clinical oncology and nuclear medicine department
        • Contact:
        • Principal Investigator:
          • Hoda H Essa, M.D.
        • Sub-Investigator:
          • Abeer F Amin, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Ipsilateral clinically diagnosed and histologically confirmed invasive breast cancer
  • Undergone total mastectomy and axillary dissection T 3-4 and/or 4 or more positive axillary lymph nodes.
  • Fit for chemotherapy ( if indicated) , endocrine therapy (if indicated), and postoperative irradiation.
  • Written informed concent.
  • C T3-4 , or C N2, or pathological positive axillary lymph nodes during mastectomy for patients who had received neoadjuvant chemotherapy or hormone therapy.
  • No supraclavicular or internal mammary nodes metastases.
  • No distant metastases .Enrollment date no more than 8 months after surgery or no more than 2 months after chemotherapy for patients who did't receive neoadjuvant therapy.
  • Enrollment date no more than 2 months after surgery for patients who had received neoadjuvant systemic therapy and did't need adjuvant chemotherapy.

Exclusion Criteria:

  • Patients who undergone previous irradiation to the ipsilateral chest wall and supraclavicular region
  • Previous or concurrent malignant other than non melanomatous skin cancer
  • Bilateral breast cancer.
  • Immediate or delayed ipsilateral breast cancer reconstruction.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group (1)
Hypofractionated radiotherapy women with T3-4 and /or 4 or more axillary nodes involvement post mastectomy. Hypofractionated radiotherapy 43,5 GY/15 fractions (f) /3w. to chest wall and supraclavicular nodal region.
Radiation: Hypofractionated radiotherapy

Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.

.
Active Comparator: group(2)
Conventional fractionated radiotherapy breast cancer women with T3-4 and/ or 4 or more axillary nodes involvement post mastectomy. Conventional fractionated radiotherapy 50 Gray(GY)/25 fractions (f)/5w to chest wall and supraclavicular nodal region.
Radiation: Conventional fractionated radiotherapy
50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Locoregional control rate ipsilateral chest wall, axilla, supraclavicular and internal mammary nodal relapse.
Time Frame: two years
60 female patients with high risk post mastectomy breast cancer will divided randomly into two equal groups One group will received hypofractionated (HF) regimen of postoperative radiotherapy, and group two will receive conventional fractionated (CF) regimen of postoperative local radiotherapy. in high risk breast cancer , comparison between the two treated groups.
two years
Frequency of local recurrence.
Time Frame: one year
Comparison between the treatment groups.
one year
Toxicity outcome/ side affects that may occur with breast radiation therapy.
Time Frame: two years
Comparison between the two treatment groups regarding breast irradiation toxicity outcomes and its frequency.
two years
Histopathologic grades of the tumor.
Time Frame: one year
Comparison between the two treatment groups.
one year
Pathological tumour size (pT stage classification)
Time Frame: one year
cT 3-4
one year
Pathological node status (pN stage classification) (cN)
Time Frame: one year
cN 2 (4 or more positive axillary lymph nodes.
one year
Frequency of distant metastasis
Time Frame: two years
Compare two treatment groups regarding the frequency of distant metastasis.
two years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival.
Time Frame: two years
Any deaths
two years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ahmed Ahm

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2017

Primary Completion (Anticipated)

September 1, 2018

Study Completion (Anticipated)

September 1, 2019

Study Registration Dates

First Submitted

October 2, 2017

First Submitted That Met QC Criteria

October 22, 2017

First Posted (Actual)

October 24, 2017

Study Record Updates

Last Update Posted (Actual)

October 24, 2017

Last Update Submitted That Met QC Criteria

October 22, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 17200012

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe